JMP Securities Downgrades Ambrx Biopharma to Market Perform

Benzinga ·  Jan 10 05:23

JMP Securities analyst Reni Benjamin downgrades Ambrx Biopharma (NASDAQ:AMAM) from Market Outperform to Market Perform.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment